Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		6 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013	Mar. 31, 2012
REVENUES
Net product sales	$ 16,535,059	$ 9,141,873	$ 31,414,321	$ 14,630,636
Revenues from royalties	899,129	898,515	2,525,139	2,574,635
Revenues from research grant services			15,000
Total revenues	17,434,188	10,040,388	33,954,460	17,205,271
OPERATING EXPENSES
Cost of product sales	933,426	534,345	1,771,555	844,148
Cost of research grant services	69,090		78,488
Research and development	8,874,298	6,395,155	15,522,389	10,139,670
Selling and marketing	16,061,408	14,814,014	29,583,827	28,596,850
General and administrative	6,978,684	5,346,990	13,517,087	10,639,173
Total operating expenses	32,916,906	27,090,504	60,473,346	50,219,841
Loss from operations	(15,482,718)	(17,050,116)	(26,518,886)	(33,014,570)
OTHER INCOME (EXPENSE)
Interest income	15,065	7,882	34,396	22,173
Interest expense	(1,059,245)		(2,118,490)
Other, net	197	75	197	4,081
Net loss	$ (16,526,701)	$ (17,042,159)	$ (28,602,783)	$ (32,988,316)
Basic and diluted net loss per share	$ (0.12)	$ (0.13)	$ (0.21)	$ (0.25)
Basic and diluted weighted average number of common shares outstanding	139,173,746	133,463,300	137,959,958	130,683,671